TB-500

What it is

Thymosin beta-4 is a naturally occurring protein of 43 amino acids, roughly 4,900 daltons, present in most human cells and found in high concentration in platelets and in wound fluid. Its best-characterized job is binding monomeric actin — sequestering it and regulating how the cell’s internal scaffolding is assembled and disassembled.

TB-500 is not thymosin beta-4. It is a synthetic fragment corresponding to the actin-binding region of the parent molecule, usually described as the acetylated heptapeptide Ac-LKKTETQ (residues 17–23), around 843 daltons. The FDA’s own bulk-substance listings name it precisely: Thymosin beta-4, Fragment (TB-500). This distinction matters more than most marketing acknowledges. A great deal of the research cited in support of TB-500 was performed with full-length thymosin beta-4, not the fragment, and independent testing has found that material sold as “TB-500” varies considerably in what it actually contains.

The mechanisms described in preclinical work follow from the actin biology: sequestration of monomeric actin and facilitation of cell migration into injured tissue, promotion of endothelial cell migration and new vessel formation, downregulation of several inflammatory cytokines, and upregulation of laminin-5 in healing epithelium. Whether that produces a meaningful clinical difference in a human joint or tendon has not been established.

What the research shows

The evidence needs to be split in two, because the two molecules have very different records.

Full-length thymosin beta-4 has a genuine human clinical trial history — all of it involving the peptide applied directly to the injured surface, not injected systemically. Trials sponsored by RegeneRx and its partners included a European prospective randomized study in venous stasis ulcers published in 2007, a Phase 2 study in pressure ulcers, a Phase 2 topical gel program in epidermolysis bullosa (RGN-137), and an ophthalmic program using preservative-free eye drops (RGN-259). Results have been genuinely mixed: a Phase 3 trial in neurotrophic keratopathy reported positive healing outcomes and was published in the peer-reviewed literature, while the dry eye program produced inconsistent results across endpoints and a later Phase 3 trial, SEER-3, missed its primary endpoint. No thymosin beta-4 product has been approved by the FDA.

TB-500, the fragment, has no completed randomized controlled trial in humans. The case for using it in tendon, ligament, or muscle injury rests on animal work — rodent models of cardiac, corneal, dermal, and tendon repair — and on clinical impression. The frequently cited studies showing activation of epicardial progenitor cells were performed with full-length thymosin beta-4.

On safety, there is no controlled human safety data for systemic TB-500. The FDA’s stated concerns about compounded peptides — immunogenicity arising from aggregation and peptide-related impurities — apply directly. And because the proposed mechanism involves cell migration and new blood vessel formation, the same unresolved theoretical question raised about angiogenic compounds and tumor blood supply applies here. It has not been demonstrated in humans, but it is discussed explicitly with any patient who has a personal or family cancer history.

Who may be a candidate

Adults with a slow-resolving soft-tissue injury that has not responded to an adequate course of conventional care
Post-surgical or post-injury patients whose recovery has plateaued and in whom a correctable structural cause has been excluded
Patients under evaluation for chronic musculoskeletal restriction in which scar and fibrotic tissue appear to be part of the picture
Patients who understand they are considering an investigational compound and are willing to be monitored

It is generally not appropriate in active or recent malignancy, in pregnancy or breastfeeding, for drug-tested athletes or active-duty service members, or for anyone unwilling to commit to follow-up.

What treatment looks like here

Evaluation. A full history, physical examination including osteopathic structural assessment, and review of prior imaging come first. Persistent soft-tissue problems very often have a mechanical explanation — a joint that is not moving, a chain that is compensating, a loading pattern that keeps re-injuring the same tissue.

Laboratory work. Baseline testing generally includes a complete blood count, comprehensive metabolic panel, hs-CRP, hemoglobin A1c, vitamin D, iron studies and ferritin, thyroid function, and sex hormones where indicated.

Route and cadence. When used, TB-500 is given by subcutaneous injection, sometimes directed near the affected region. It is paired with osteopathic manipulative treatment and a structured loading program rather than used in place of them.

Monitoring. Labs are repeated on a defined schedule and progress measured objectively — range of motion, strength, validated pain scores, return-to-activity milestones — against a stopping point set in advance. If those measures have not changed by then, the trial ends. Sourcing is part of the discussion, because material purchased online as a “research chemical” is not manufactured or tested to pharmaceutical standards.

FDA & regulatory status

TB-500 is not an FDA-approved drug. Neither is thymosin beta-4. Neither is approved for wound healing, tendon injury, joint pain, or any other indication in the United States.

The compounding picture has moved recently:

In 2023, the FDA placed Thymosin beta-4, Fragment (TB-500) in Category 2 of its 503A bulk drug substances review — substances that may present significant safety risks — citing potential immunogenicity from aggregation and peptide-related impurities.
In April 2026, it was removed from Category 2 along with eleven other peptides. Removal did not add it to the 503A Bulks List. It defaults to unapproved-new-drug status, a gray area rather than an authorization.
On July 23, 2026, the FDA’s Pharmacy Compounding Advisory Committee voted 8 to 6, with one abstention, to recommend TB-500 for inclusion on the 503A Bulks List, as nominated for wound healing.
That vote is advisory only. The FDA is not bound by it, and notice-and-comment rulemaking would have to be completed before anything changes in practice — potentially 2027 or later.
Inclusion on the 503A Bulks List, if it happens, would not constitute FDA approval. It governs what a compounding pharmacy may use as a starting material; it is not a finding of efficacy.
TB-500 does not appear on the 503B Bulks List, so it is not available through outsourcing facilities.
The World Anti-Doping Agency has prohibited TB-500 since 2018 under class S2.3, growth factors and growth factor modulators, in and out of competition. It carries a specified-substance designation, which can affect the length of a sanction but does not make it permitted.

Questions we get

Is TB-500 the same thing as thymosin beta-4? No, and this is the most common misunderstanding. Thymosin beta-4 is the full 43-amino-acid protein. TB-500 is a short synthetic fragment of its actin-binding region. Most of the human clinical trial data belongs to the full-length molecule and was generated using topical application, not injection.

Is TB-500 FDA-approved? No. It is not approved for any indication, and neither is thymosin beta-4. As of August 2026 TB-500 is also not on the 503A Bulks List, though an FDA advisory committee recommended in July 2026 that it be added.

The eye and wound trials looked positive. Does that mean it will help my shoulder? It does not follow. Those trials used a different molecule, applied directly to the injured surface, in a different tissue. Extrapolating from a topical ophthalmic result to an injected musculoskeletal one is the kind of inference that proves wrong often enough that we do not make it.

Is it safe? That claim cannot responsibly be made. There is no controlled human safety data for systemic TB-500. Anything used here is prescribed by a physician after individual evaluation, with laboratory monitoring and scheduled reassessment.

Can it be combined with BPC-157? Blends containing both are widely marketed, and there are no controlled trials of any of them. Combining two investigational compounds also makes it impossible to attribute a change — or an adverse effect — to either one, which is a real drawback when the point is to learn something.

8 — Muscle, Joint, Mobility & Pain, the reason most patients ask about it
10 — Sleep, Recovery & Restoration, where tissue repair actually happens
2 — Inflammation, Disease Risk & Prevention, since stalled healing and chronic inflammation usually travel together
1 — Comprehensive Health Assessment & Foundation, because the evaluation frequently identifies a more treatable cause

Next step

The productive first step is an evaluation, not a prescription. Dr. St. Marie will examine you, review your imaging and history, order appropriate laboratory work, and give you a direct assessment of what is limiting your recovery — and whether an investigational peptide has any place in addressing it.

Candidacy for TB-500 is determined by Dr. St. Marie through comprehensive evaluation and lab work. It is not appropriate for everyone.

To schedule, call 407-506-4776 or book online. Osteopathic Health of Orlando, 4625 Halder Lane, Suite C, Orlando, FL 32814.